Potential role of tirabrutinib as part of an optimal treatment strategy for lymphomatosis cerebri: illustrative case.

Authors

Mari Ono, Akihiro Inoue, Yukihiro Miyazaki, Yawara Nakamura, Teruyuki Ohno, Mashio Taniwaki, Hajime Yano, Hideaki Watanabe, Takeharu Kunieda

Published in

Journal of neurosurgery. Case lessons. Volume 11. Issue 26. Jun 29, 2026. Epub Jun 29, 2026.

Abstract

Lymphomatosis cerebri (LC) is a rare variant of primary CNS lymphoma characterized by diffuse fluid-attenuated inversion recovery (FLAIR) hyperintensity on MRI.
A 71-year-old woman presented with a 1-month history of nausea. On admission, she showed no focal neurological deficits except dizziness. MRI revealed diffuse FLAIR hyperintensity from the cerebellar vermis to the midbrain involving the right temporal and parietal lobes, accompanied by partial diffusion-weighted imaging (DWI) hyperintensity and no gadolinium enhancement. 18F-fluorodeoxyglucose positron emission tomography demonstrated no abnormal uptake, and CSF analysis demonstrated elevated β2-microglobulin (MG) levels and an MYD88 mutation on cell-free DNA that leaked into the CSF. A targeted biopsy of the DWI-hyperintense region confirmed CD20-positive diffuse large B-cell lymphoma. She underwent therapy with rituximab, methotrexate, procarbazine, and vincristine followed by high-dose cytarabine, achieving temporary remission; however, relapse occurred 1 month after consolidation therapy. Tirabrutinib was initiated, resulting in complete radiological resolution for 5 months. LESSONS Diffuse white matter abnormalities without enhancement should raise suspicion of LC and prompt targeted biopsy, particularly from DWI-hyperintense regions. CSF β2-MG and MYD88 mutation analysis provide valuable diagnostic clues for distinguishing LC from malignant glioma. This case also suggests a potential therapeutic role for tirabrutinib in early-relapsing LC. https://thejns.org/doi/10.3171/CASE26337.

PMID:
42372315
Bibliographic data and abstract were imported from PubMed on 30 Jun 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.